Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC
BPC-157
A synthetic pentadecapeptide with no FDA-approved drug product. It appears on FDA's table of bulk drug substances whose compounding nominations were withdrawn, and is named individually on the WADA Prohibited List.
Also listed as: Pentadecapeptide BPC 157, PL-14736, Bepecin
Chemical identity
- Compound class
- Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC
- Sequence
- GEPPPGKPADDAGLV
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.5 g/mol
- CAS number
- 137525-51-0
- PubChem CID
- 9941957
- Research categories
- Peptide fragments, Preclinical research compounds
United States regulatory status
No FDA-approved product
- No approved drug product exists in Drugs@FDA.
- Listed on FDA's table of bulk substances nominated for compounding and subsequently withdrawn by the nominator. FDA's published concerns include immunogenicity risk, peptide-related impurities, and complexity of API characterisation.
- Considered at FDA's Pharmacy Compounding Advisory Committee meeting of 23 July 2026 for possible inclusion on the 503A Bulks List. No vote outcome had been published on FDA's meeting page at the time of review.
- Not on the 503A Bulks List.
Anti-doping status
Named in Class S0 (Non-Approved Substances). Prohibited at all times; Specified Substance.
Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.
Sources
Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built